Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common ...

Monopar Therapeutics announces pricing of $135M offering

Monopar Therapeutics raises $100M in stock offering to fund R&D, clinical trials, and a stock buyback.

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common ...

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics”, “Monopar”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered…

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Monopar Therapeutics (NASDAQ:MNPR)

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar Therapeutics", "Monopar", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered offering of 1,034,433 shares of its common stock at an offering price of $67.67 per share and, in lieu of shares of common stock t…